Physician profile
Robert A Ruffini
NPI 1407920408
$3,309.50
in general payments reported to CMS, 2019-2025
48 companies · $809 in 2025
The $809 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $322 · 2021: $283 · 2022: $134 · 2023: $352 · 2024: $427 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $519.85 | 2019-2025 | Xifaxan |
| Abbvie INC. | $477.47 | 2019-2024 | Linzess, Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $212.62 | 2019-2022 | |
| Novo Nordisk INC | $201.72 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $197.51 | 2019-2021 | |
| Pfizer INC. | $130.59 | 2023-2025 | |
| Celgene Corporation | $110.70 | 2022-2024 | Zeposia |
| Braintree Laboratories, INC. | $82.26 | 2022-2025 | Suflave |
| Insulet Corporation | $74.76 | 2025 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $67.99 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $65.30 | 2019-2020 | |
| Genzyme Corporation | $63.13 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $57.66 | 2019-2020 | |
| Corcept Therapeutics | $56.58 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $55.69 | 2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ruffini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.